Botanix Pharmaceuticals Limited (BOT.AX)
ASX · AUD · Healthcare · Biotechnology
A$0.011 (-15.38%) as of
Key statistics
- Market cap
- 30.38M
- Forward P/E
- ∞
- EPS (TTM)
- -0.0300
- Dividend yield
- 0.00%
- 52-week range
- 0.0110 – 0.1500
- Beta
- 0.86
- Revenue (TTM)
- 33.8M
- Profit margin
- -206.41%
- Analyst target
- A$0.48333
- Volume
- 26.47M
About Botanix Pharmaceuticals Limited
Botanix Pharmaceuticals Limited, a pharmaceutical company, engages in the research and commercialization of solutions for skin diseases and infections in Australia and the United States. The company's lead product is Sofdra (sofpironium) topical gel, a prescription anticholinergic medicine used to treat underarm sweating in adults and children 9 years of age and older. It also develops BTX 1503, a transdermal gel formulation, which is in Phase 3 clinical trial for the treatment of serious acne in adults and teenagers; BTX 1702 that is in Phase 1b/2 clinical trial to treat papulopustular rosacea; BTX 1204A for treating atopic dermatitis; and BTX 1801, which has been completed Phase 2a clinical trial for the treatment of staphylococcus aureus and methicillin resistant staphylococcus aureus. The company was incorporated in 1984 and is based in Melbourne, Australia.
- Sector
- Healthcare
- Industry
- Biotechnology
- Headquarters
- Melbourne, VIC, Australia
Financial statements (income statement, balance sheet, cash flow) and an interactive price chart are available on this page with JavaScript enabled.